Abstract:Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder worldwide, and the therapeutic is focused on several approaches including the inhibition of fibril formation by small compounds, avoiding the formation of cytotoxic oligomers. Thus, we decided to explore the capacity of compounds carrying catechol moieties to inhibit the progression of α-synuclein. Overall, the compounds rosmarinic acid (1), carnosic acid (2), carnosol (3), epiisorosmanol (4), and rosmanol (5) avoid the progression of fibril formation assessed by Thiofavine T (ThT), and atomic force microscopy images showed that morphology is influenced for the actions of compounds over fibrillization. Moreover, ITC experiments showed a Kd varying from 28 to 51 µM, the ΔG showed that the reaction between compounds and α-syn is spontaneous, and ΔH is associated with an exothermic reaction, suggesting the interactions of hydrogen bonds among compounds and α-syn. Docking experiments reinforce this idea showing the intermolecular interactions are mostly hydrogen bonding within the sites 2, 9, and 3/13 of α-synuclein, and compounds 1 and 5. Thus, compound 1, rosmarinic acid, interestingly interacts better with site 9 through catechol and Lysines. In cultured Raw 264. 7 cells, the presence of compounds showed that most of them can promote cell differentiation, especially rosmarinic acid, and rosmanol, both preserving tubulin cytoskeleton. However, once we evaluated whether or not the aggregates pre-treated with compounds could prevent the disruption of microtubules of Raw 264.7 cells, only pre-treated aggregates with rosmarinic acid prevented the disruption of the cytoskeleton. Altogether, we showed that especially rosmarinic acid not only inhibits α-syn but stabilizes the remaining aggregates turning them into not-toxic to Raw 264.7 cells suggesting a main role in cell survival and antigen processing in response to external α-syn aggregates.

Myricetin inhibits α‐synuclein amyloid aggregation by delaying the liquid‐to‐solid phase transition

Myricetin Inhibits -Synuclein Amyloid Aggregation by Delaying the Liquid-to-Solid Phase Transition

Myricetin slows liquid–liquid phase separation of Tau and activates ATG5-dependent autophagy to suppress Tau toxicity

Myricetin mitigates motor disturbance and decreases neuronal ferroptosis in a rat model of Parkinson's disease

Myricetin Prevents Fibrillogenesis of Hen Egg White Lysozyme

Hybrids of polyphenolic acids and xanthone, the potential preventive and therapeutic effects on PD: Design, synthesis, in vitro anti-aggregation of α-synuclein, and disaggregation against the existed α-synuclein oligomer and fibril

Myricetin prevents high molecular weight Aβ1-42 oligomer-induced neurotoxicity through antioxidant effects in cell membranes and mitochondria

Curcumin Inhibits α-Synuclein Aggregation by Acting on Liquid-Liquid Phase Transition

Liquid-liquid phase separation and liquid-to-solid transition mediate α-synuclein amyloid fibril containing hydrogel formation

Inhibitor discovery targeting the intermediate structure of β-amyloid peptide on the conformational transition pathway: Implications in the aggregation mechanism of β-amyloid peptide

Manganese promotes α-synuclein amyloid aggregation through the induction of protein phase transition

Rosmarinic acid turned α-syn oligomers into non-toxic species preserving microtubules in Raw 264.7 cells

Inhibitor Development for α-Synuclein Fibril's Disordered Region to Alleviate Parkinson's Disease Pathology

Therapeutic potential of Coumarin-polyphenolic acid hybrids in PD: inhibition of α-Syn aggregation and disaggregation of preformed fibrils, leading to reduced neuronal inclusion formation

Trehalose Inhibits Fibrillation of A53T Mutant Alpha-Synuclein and Disaggregates Existing Fibrils

Molecular mechanism of α-synuclein aggregation on lipid membranes revealed

Myricetin Prevents Dopaminergic Neurons from Undergoing Neuroinflammation-Mediated Degeneration in a Lipopolysaccharide-Induced Parkinson's Disease Model

Myricitrin alleviates MPP⁺-induced mitochondrial dysfunction in a DJ-1-dependent manner in SN4741 cells.

Myricetin ameliorates cognitive impairment in 3×Tg Alzheimer's disease mice by regulating oxidative stress and tau hyperphosphorylation

Inhibition effects of tanshinone on the aggregation of alpha-synuclein

β-synuclein regulates the phase transitions and amyloid conversion of α-synuclein